静脉注射尼科兰迪尔治疗急性不补偿性心力衰竭患者:随机对照试验的元分析
1Department of Emergency, The Seventh People's Hospital of Shaoxing, Shaoxing, China.
Scandinavian cardiovascular journal : SCJ
|June 28, 2023
概括
静脉注射的尼科兰迪尔在急性不补偿性心力衰竭 (ADHF) 中显示出前景. 这一元分析发现它可以改善症状,减少心脏生物标志物,并降低主要的心血管不良事件,而不会增加不良事件.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 试点研究表明,静脉注射尼科兰迪尔对急性不补偿性心力衰竭 (ADHF) 有好处.
- 在ADHF中静脉注射尼科兰迪尔的临床证据仍然有限.
研究的目的:
- 总结了静脉注射尼科兰迪尔在ADHF治疗中的疗效和安全性.
- 提供当前临床证据的全面概述.
主要方法:
- 随机对照试验 (RCT) 的系统审查和元分析.
- 搜索了PubMed,Embase,Cochrane的图书馆,万芳和CNKI的数据库.
- 采用随机效应模型进行数据合成.
主要成果:
- 静脉注射尼科兰迪尔在24小时内显著改善呼吸障碍.
- 降低了血清B型性尿素和N终端proBNP水平.
- 改善左心室喷射率和E/e'比率.
- 在90天的随访期间,主要不良心血管事件减少了45%.
- 与对照组相比,与治疗相关的不良事件没有显著差异.
结论:
- 静脉注射尼科兰迪尔似乎是ADHF的有效治疗方法.
- 在ADHF中,静脉注射尼科兰迪尔的安全性概况与对照疗法相当.
- 进一步的研究可能会巩固其在ADHF管理中的作用.
相关概念视频
Heart Failure V: Medical Management
15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
Acute Coronary Syndrome IV: Interprofessional Care
13
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
13
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
Acute Coronary Syndrome III: Diagnostic Studies
11
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
11
Heart Failure Drugs: Inotropic Agents
640
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
640
Acute Coronary Syndrome V: Nursing Management
18
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
18


